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Toll-like receptors (TLRs) such as TLR2 and TLR4 have been implicated in host response to mycobacterial infec-
tion. Here, mice deficient in the TLR adaptor molecule myeloid differentiation factor 88 (MyD88) were infected 
with Mycobacterium tuberculosis (MTB). While primary MyD88–/– macrophages and DCs are defective in TNF, IL-12, 
and NO production in response to mycobacterial stimulation, the upregulation of costimulatory molecules CD40 
and CD86 is unaffected. Aerogenic infection of MyD88–/– mice with MTB is lethal within 4 weeks with 2 log10 
higher CFU in the lung; high pulmonary levels of cytokines and chemokines; and acute, necrotic pneumonia, 
despite a normal T cell response with IFN-γ production to mycobacterial antigens upon ex vivo restimulation. 
Vaccination with Mycobacterium bovis bacillus Calmette-Guérin conferred a substantial protection in MyD88–/– 
mice from acute MTB infection. These data demonstrate that MyD88 signaling is dispensable to raise an acquired 
immune response to MTB. Nonetheless, this acquired immune response is not sufficient to compensate for the 
profound innate immune defect and the inability of MyD88–/– mice to control MTB infection.
Introduction
Tuberculosis caused by Mycobacterium tuberculosis (MTB) is a highly 
infectious respiratory infection. One-third of the world’s popu-
lation has been in contact with the pathogen, but approximately 
90% of infected persons contain the infection with no overt clini-
cal symptoms (1). A better understanding of the mechanisms of the 
host that lead to protective immunity is important to develop novel 
therapies and vaccines. The need of functional APCs and T cells in 
concert with several cytokines and chemokines to initiate an adap-
tive immunity has been established (2). The recent discovery of the 
Toll-like receptor (TLR) family has provided new insights on how 
pathogens recognize and activate innate immune cells and there-
by link innate and adaptive immunity (3). MTB, its cell wall, and 
secreted components such as 19-kDa lipoprotein, lipomannan, and 
mannosylated phosphatidylinositol activate macrophages and DCs 
through TLR2 (4–9), but the contribution of other TLRs or pattern-
recognition receptors (PRRs) in MTB recognition is not excluded.
Previous in vivo investigations demonstrated that TLR2, TLR4, 
or TLR6 play no role or only a minor role in the early in vivo host 
response to MTB infection (10–13), but TLR2 (14) and TLR4 (10) 
may be required to control the chronic stage of infection. These 
data suggest a partial redundancy of TLR2, TLR4, and TLR6 or 
other TLRs that may be involved in MTB-induced cell recognition.
Most TLRs, except TLR3, use myeloid differentiation factor 88 
(MyD88), an intracellular adaptor protein of the IL-1 receptor/
IRAK pathway, to link TLR recognition with activation of IRAK 
and TRAF, translocation of NF-κB, and gene transcription (3). 
Absence of MyD88 resulted in a dramatic reduction of host resis-
tance to several infectious agents (15–21).
Here, we investigated the role of MyD88 in the control of MTB 
infection using MyD88–/– mice and demonstrate an essential 
role of MyD88 in the host response to an aerogenic infection 
with H37Rv MTB. MyD88–/– mice succumbed within 4 weeks to 
acute, necrotic pulmonary MTB infection with uncontrolled bac-
terial growth despite their ability to mount an adaptive immune 
response. Interestingly, vaccination with Mycobacterium bovis 
bacillus Calmette-Guérin (BCG) conferred initial protection 
to acute MTB infection but did not prevent chronic infection. 
Therefore, the MyD88 signaling pathway is crucial for the con-
trol of MTB infection.
Results
Reduced cytokine production, but normal upregulation of costimulatory 
molecules, in mycobacteria-activated macrophages from MyD88–/– mice. 
TNF-α and IL-12 play important roles in the control of local 
immune responses to intracellular organisms such as MTB. 
We therefore investigated the ability of MyD88–/– BM-derived 
macrophages and DCs to secrete TNF-α and IL-12 p40 in response 
to mycobacteria in vitro. TNF and IL-12 p40 production after stim-
ulation with MTB H37Rv, H37Ra, or M. bovis BCG was drastically 
reduced in MyD88-deficient macrophages and DCs compared with 
wild-type controls (Figure 1, A–D). Similar results were obtained 
after 24 or 48 hours of stimulation, except that the low cytokine 
levels were merely due to delayed kinetics (data not shown). We 
further tested the MyD88 dependence of mycobacteria-induced 
iNOS activation and demonstrate a dramatic reduction of nitrite 
production in MyD88-deficient macrophages and little effect in 
DCs (Figure 1, E and F). Furthermore, we investigated the cytokine 
production at the site of infection in the lung. TNF production by 
interstitial lung macrophages stimulated with mycobacteria was 
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undetectable, and IL-6 production was substantially reduced in 
the absence of MyD88 (Figure 1, G and H).
In contrast, the expression of the costimulatory molecules CD40 
and CD86 was upregulated in mycobacteria-infected MyD88-defi-
cient DCs (Figure 1, I and J) and macrophages (not shown) as in 
wild-type control cells. Therefore, the production of cytokines, 
but not the expression of costimulatory molecules, in response 
to mycobacterial infection is MyD88 dependent. Based on these 
results, we hypothesized that MyD88 signaling might be critical 
for the innate immune response to MTB infection.
Lethal MTB infection with necrotic pneumonia in the absence of 
MyD88. MyD88–/– mice infected with a low dose (200 CFU per 
mouse) of virulent MTB H37Rv started to lose body weight 
around 3 weeks (Figure 2A) and died within 4 weeks after infec-
tion (Figure 2B). MyD88–/– mice exhibited dramatically increased 
lung weight (Figure 2C) and a bacterial load in the lungs that 
was more than 2 log10 higher than that in wild-type controls at 4 
weeks (Figure 2D). This was accompanied by bacterial dissemina-
tion into the spleen (Figure 2E) and the liver (data not shown). 
In view of the low proinflammatory response in MTB-stimulated 
macrophages from MyD88–/– mice, we compared mice deficient 
in MyD88 with mice deficient in TNF. TNF–/– mice lost weight 
rapidly and were unable to control MTB infection, dying slightly, 
but significantly, earlier than MyD88-deficient mice (P < 0.01; 
Figure 2, A and B). Acute pulmonary infection, illustrated by a 
dramatic increase in lung weight, was found in both TNF- and 
MyD88-deficient mice 4 weeks after infection (Figure 2C). There-
fore, MyD88–/– mice are highly susceptible to MTB infection, 
similar to TNF-deficient mice (22).
Macroscopically, the lungs of MyD88–/– mice displayed pleu-
ral adhesions and effusions and large subpleural and conflu-
ent nodules (Figure 3A), as compared with wild-type controls 
Figure 1
Impaired proinflammatory cytokine and NO produc-
tion in MyD88–/– macrophages and DCs. BM-derived 
macrophages (A, C, and E) and DCs (B, D, and F) 
(5 × 105 cells/ml) prepared from MyD88–/– (white bars) 
and wild-type (black bars) mice were incubated with 
LPS (100 ng/ml), M. bovis BCG, MTB H37Ra, or MTB 
H37Rv (all at 2 bacteria per cell). After 24 hours, the 
production of TNF (A and B), IL-12 p40 (C and D), 
or nitrite (E and F) was determined in the super-
natant by ELISA or Griess reaction. TNF and IL-6 
production by pulmonary macrophages stimulated in 
the same conditions was also measured (G and H). 
Upregulation of CD40 (I) and CD86 (J) expression 
by DCs stimulated with LPS or M. bovis BCG were 
analyzed by FACS. Data are from 1 experiment, rep-
resentative of 3 independent experiments with n = 2 
mice per genotype; mean values ± SD are shown. 
MFI, mean fluorescence intensity.
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(Figure 3B). Microscopic investigation of the lungs of MyD88–/– 
mice revealed massive mononuclear and neutrophil infiltra-
tions with extensive confluent necrosis in the absence of proper 
granuloma formation at 27 days (Figure 3, C–F) and abundant 
mycobacteria in macrophages and also in the extracellular space 
(Figure 3, G–H). In the liver and spleen, only a few small granuloma 
were found as a sign of dissemination of infection in both MyD88-
deficient and wild-type mice (data not shown). The observed lung 
lesions are similar to those induced by mycobacterial infection in 
TNF-deficient mice (22, 23). Thus, in the absence of MyD88, mice 
developed massive necrosis and infiltration of inflammatory cells 
in the lungs with uncontrolled MTB growth.
Increased recruitment of myeloid cells in MyD88–/– mice. In view of 
the acute and uncontrolled pulmonary infection of MyD88–/– 
mice, we asked how the recruitment of immunoinflamma-
tory cells in the lung parenchyma is modulated in the absence 
of MyD88. The total number of cells recovered from lung of 
both groups was comparable. Flow cytometric analysis revealed 
similar amounts of CD4+ and CD8+ T cells expressing the acti-
vation marker CD44 in MyD88-deficient and control lungs at 4 
weeks of infection (Figure 4A). Consistent with the histology, we 
found increased numbers of Ly6G+ and CD11b+ cells in the lung 
homogenates of MyD88–/– mice (Figure 4B), with expression of 
class II on the CD11b+ cells (Figure 4C). CD11c+ cells were nor-
mally recruited and activated in the absence of MyD88 (Figure 
4, B and C). Thus, the data demonstrate that the high infectious 
burden in MTB-infected MyD88-deficient mice is accompanied 
by a vigorous inflammatory response with 
increased neutrophils and macrophages, and 
apparently normal recruitment and activation 
of T lymphocytes in the lung, that occurs in 
the absence of MyD88 signaling.
Activation of T cells in MyD88–/– mice. As 
MyD88 signaling has been shown to be 
required for an antigen-specific Th1 immune 
response (18), we asked whether the T cell 
responses in vivo and in vitro to mycobacterial 
antigens are altered in vaccinated MyD88–/– 
mice. First, we tested delayed type hypersensi-
tivity (DTH) reaction in mice vaccinated with 
M. bovis BCG. DTH-induced swelling was 
absent in MyD88–/– mice, as in naive mice, 
although a clear response was measured in 
vaccinated wild-type mice (Figure 5A). The 
absence of DTH-induced swelling in MyD88–/– 
mice might be due to the impaired production 
of proinflammatory cytokines rather than to 
a reduced cell-mediated immune response. 
Therefore, we tested the antigen-specific 
response in vitro by restimulation of splenic 
T cells from wild-type and MyD88–/– animals 
vaccinated with M. bovis BCG at 4 weeks. 
Antigen-specific IFN-γ secretion was induced 
in both MyD88–/– and wild-type splenocytes 
restimulated with soluble BCG antigens with 
no significant statistical difference but was 
not induced in splenocytes restimulated with 
unrelated Listeria antigens (Figure 5B). Simi-
lar results were obtained with splenic CD3+ 
purified T cells upon stimulation with soluble 
BCG antigens, in the presence of either wild-type or MyD88-defi-
cient macrophages (data not shown). In order to further dem-
onstrate the T cell origin of the IFN-γ response, the intracellular 
expression of IFN-γ in pulmonary T cells was analyzed. Upon 
BCG infection, both MyD88–/– and wild-type mice exhibited 
IFN-γ–producing CD4 T cells and, to a lesser extent, CD8 T cells 
(Figure 5C and Table 1), although the percentages of IFN-γ–pro-
ducing T cells seemed slightly lower in MyD88-deficient mice. 
Furthermore, after BCG vaccination, the percentage of CD4+ 
spleen T cells expressing IFN-γ intracellularly upon restimulation 
with BCG soluble antigens was similar in MyD88–/– and in wild-
type mice (4.0% and 3.6%, respectively) and higher than in unvac-
cinated MyD88–/– and control mice (2.2% and 2.9%, respectively). 
The response was specific, because lower response was obtained 
after restimulation with heat-killed Listeria monocytogenes (HKLM) 
(1.3–2.4%). Therefore, antigen-specific activation of T cells and 
induction of a Th1 response to mycobacterial antigens do occur 
in the absence of MyD88.
BCG immunization protects MyD88–/– mice from acute MTB infec-
tion. To confirm further that MyD88-dependent signaling is not 
required for antigen-specific T cell response, we tested whether 
BCG immunization would confer protection to a challenge with 
aerogenic MTB (200 CFU). We found that BCG immunization 5 
weeks prior to the MTB challenge conferred protection against 
acute infection. At 4 weeks after MTB challenge, MyD88–/– mice 
behaved like wild-type controls, while nonimmunized MyD88–/– 
mice rapidly lost weight (Figure 6A). Vaccinated MyD88–/– mice 
Figure 2
MyD88–/– mice are unable to control an MTB infection. MyD88–/– (open circles), TNF–/– (open 
squares), and wild-type (filled squares) mice were exposed to a low aerogenic dose of MTB 
H37Rv (200 CFU per mouse i.n.) and monitored for body weight (A; mean values of n = 6–8 
mice per group from 1 representative experiment out of 7 independent experiments) and 
survival (B; n = 13–24 mice pooled from several experiments; P ≤ 0.01 between MyD88–/– or 
TNF–/– mice and wild-type controls, and between TNF- and MyD88-deficient mice). (C) Lung 
wet weight of TNF–/– mice (gray bars), MyD88–/– mice (white bars), and wild-type controls 
(black bars) were measured 17 and 27 days after infection. The numbers of viable bacteria 
present in the lungs (D) and spleen (E) of MyD88–/– (white bars) and wild-type (black bars) 
mice were determined after 27 days of infection (mean ± SD of n = 3–4 lung or n = 5–7 
spleen samples from 1 representative experiment out of 2 or 3 independent experiments, 
respectively; **P ≤ 0.01).
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started to succumb between 6 and 10 weeks after MTB challenge 
(Figure 6B). Lung weights at 4 weeks after MTB challenge were 
not increased in vaccinated MyD88–/– mice (Figure 6C), and 
mycobacterial burden in the lungs was comparable to that of 
wild-type controls (Figure 6D). We verified that BCG infection 
did not induce mortality in MyD88-deficient mice, which sur-
vived the 8-month observation period, although they developed 
chronic pneumonitis (2 × 106 CFU i.v.) (24).
Macroscopically, the lungs of BCG-vaccinated MyD88-deficient 
mice appeared normal at 4 weeks after MTB challenge, with no 
large nodules on the pleura, unlike nonvaccinated MyD88-defi-
cient mice (Figure 7, A and B). The lung micrographs of vacci-
nated MyD88-deficient mice revealed a robust mononuclear cell 
infiltration with abundant focal and perivascular lymphocytes, 
activated macrophages, and no signs of necrosis, suggesting that 
infection was controlled (Figure 7, C and E). Vaccinated wild-type 
mice displayed similar morphologic signs of an active immune 
response with lymphocyte recruitment (Figure 7, D and F) as the 
vaccinated MyD88-deficient mice. 
The flow cytometric analysis revealed 
some increase in the relative recruit-
ment of T cells after BCG immuniza-
tion in MyD88–/– and wild-type mice; 
however, this was not apparent in 
absolute numbers of lung-infiltrat-
ing lymphocytes (Figure 8, A and B) 
in vaccinated MyD88–/– and wild-type 
mice as compared with nonvaccinat-
ed mice (Figure 4). Furthermore, the 
relative recruitment and activation of 
myeloid cells was comparable in both 
vaccinated groups, although abso-
lute numbers of myeloid cells were 
lower for vaccinated MyD88-defi-
cient mice (Figure 8, B and C), likely 
due to the lower number of infiltrat-
ing cells obtained from the lungs of 
infected MyD88-deficient mice at 
4 weeks after MTB challenge. Few 
mycobacteria were detected in the 
lungs of vaccinated MyD88-deficient 
mice at this stage (data not shown). 
At the time of death, however, vac-
cinated MyD88–/– mice presented 
large, confluent pulmonary nod-
ules; reduced airspace with conflu-
ent, necrotic lesions; and abundant 
mycobacteria (data not shown), indi-
cating that they succumbed to overwhelming infection. These 
data suggest that T cell immunity can confer an initial protective 
Figure 3
MyD88–/– mice exhibit acute necrotic pneumonia with large nodules but defective granuloma formation 
in response to MTB infection. Lung tissue from MyD88–/– (A, C, E, and G) and wild-type (B, D, F, and 
H) mice was analyzed 27 days after MTB H37Rv infection (200 CFU i.n.). Lungs of MyD88–/– mice 
showed large and confluent nodules (A) in comparison with those of wild-type mice (B). Microscopic 
examination showed extensive inflammation and necrosis in infected MyD88–/– lungs (C–F; H&E) with 
abundant mycobacteria in the extracellular space (G and H; Ziehl-Neelsen). Low-power micrographs 
of representative lung sections are shown in C and D (magnification, ×50), and higher magnification 
shows details in E–H (magnification, ×400).
Figure 4
T lymphocyte and myeloid cell recruitment and activation in the lung of 
MyD88–/– infected mice. Infiltrating cells from the lungs of MyD88–/– and 
control mice were isolated 27 days after infection and analyzed by 
flow cytometry for the expression of CD4, CD8, CD44, CD11b, CD11c, 
Ly-6G, and MHC class II IA–IE. Typical dot plots of FACS analysis are 
shown for CD44 expression in CD4+ and CD8+ T cells (A; gated on T 
lymphocytes). Graphic representations of the different leukocyte popu-
lations (B) and of the expression of MHC class II on APCs (C) are 
shown. Results are expressed as absolute numbers of positive cells. 
Mean ± SD from 2 MyD88–/– mice are shown and are representative of 
2 independent experiments.
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effect in the absence of the MyD88 pathway, but this is not suf-
ficient to compensate the profound defect of the innate immune 
response in MyD88–/– mice.
Reduced cytokine and chemokine pulmonary levels in MTB-infected 
MyD88–/– mice upon vaccination. MyD88-deficient cells show 
a defect in TNF and IL-12 p40 production in response to 
mycobacteria in vitro (Figure 1). Further, we showed impaired 
early in vivo TNF production in the airways of MyD88-deficient 
mice 6 hours after local exposure to killed mycobacteria (data 
not shown). However, massive leukocyte infiltration in the lungs 
of MTB-infected MyD88-deficient mice at 4 weeks after MTB 
challenge suggested an increase in the production of cytokines 
and/or chemokines. In order to assess the local cytokine and 
chemokine levels, we homogenized infected lungs at 25 days after 
MTB inoculation and assayed the supernatants. High levels of 
IL-1β, IFN-γ, and TNF-α were detected in the lungs of nonvac-
cinated MyD88–/– mice, whereas cytokine levels were lower upon 
vaccination in MyD88-deficient mice and in wild-type mice (Fig-
ure 9, A–C). Low levels of IL-10, IL-12, and TGF-β were detected 
in all 4 groups of mice (data not shown).
Levels of the chemokines MIP-1α and MCP-1 were significantly 
elevated in the lungs of nonvaccinated MyD88–/– mice as com-
pared with vaccinated MyD88–/– mice and wild-type controls (Fig-
ure 9, D and E). RANTES levels were high in all 4 groups, but most 
elevated in lungs of nonvaccinated MyD88–/– mice (Figure 9F). 
Therefore, nonvaccinated MyD88-deficient mice showed high-
ly increased levels of IL-1β, IFN-γ, TNF-α, MIP-1α, and MCP-1 
as compared with control mice. Cytokine and chemokine levels 
were lower upon vaccination, concomitant with the reduced bac-
illary burden in these animals.
Discussion
We show here that the MyD88-mediated signaling pathway is 
critically involved in the development of innate, but not adap-
tive, immunity in response to MTB infection. Activation of APCs 
by mycobacteria with the production of cytokines and nitrite is 
MyD88 dependent, while the expression of costimulatory mol-
ecules on APCs is MyD88 independent. Most significantly, the T 
cell response to mycobacterial antigens, with IFN-γ production, is 
conserved, suggesting a MyD88-independent induction of adap-
tive immunity to live mycobacteria. This may be a peculiarity of 
responses to intracellular pathogens, as the induction of an anti-
Figure 5
Reduced DTH response, but normal IFN-γ secretion, to mycobacterial antigens stimulation in MyD88–/– mice. (A) Cutaneous DTH response 
was performed 3 weeks after vaccination with M. bovis BCG (105 CFU s.c.; v) by assessing the footpad swelling in response to PPD injection as 
described. Paw swelling is defined as the difference in thickness between the left paw injected with PPD and the right paw injected with saline. DTH 
responses of nonvaccinated MyD88–/– and MyD88+/+ mice are shown as control (nv). Data are expressed as mean ± SD (n = 7–8) and are from 1 
representative experiment out of 2. **P ≤ 0.01. (B) For the T cell response, spleen cells from M. bovis BCG–vaccinated MyD88-deficient and control 
mice were harvested 4 weeks after inoculation (105 CFU s.c.) and were restimulated in vitro in the presence of soluble BCG antigens (SupBCG, 
10 μg/ml) or unrelated antigen (HKLM, 100 bacteria per cell). Naive MyD88–/– mice and wild-type mice were used as negative control. IFN-γ produc-
tion was quantified in the supernatants after 48 hours of incubation. Results are mean ± SD from n = 2 mice per genotype and are representative 
of 3 independent experiments. (C) Intracellular IFN-γ staining of CD4+ or CD8+ splenocytes from BCG-infected MyD88-deficient and control mice 
4 weeks after infection, restimulated for 18 hours in the presence of soluble BCG antigens (SupBCG, 10 μg/ml) or unrelated antigen (HKLM, 100 
bacteria per cell). Typical dot blots are shown for CD4+ T cells (numbers indicate percentage of IFN-γ–positive CD4+ cells).
Table 1
Intracellular IFN-γ staining of CD4+ or CD8+ splenocytes from 
BCG-infected MyD88-deficient mice upon restimulation
IFN-γ+  Positive cells (%)  MFI
Cell type Medium SupBCG HKLM  Medium SupBCG HKLM
CD4+
MyD88–/– 2.06 4.80 2.10 70.86 120.42 75.02
MyD88+/+ 1.92 7.88 3.05 66.90 114.11 78.52
CD8+
MyD88–/– 0.18 0.84 0.32 55.73 134.32 48.26
MyD88+/+ 0.29 2.83 1.94 49.14 163.41 97.53
Infection and ex vivo restimulation of splenocytes were carried out as 
in Figure 5C. Results are expressed as percentage of IFN-γ–positive 
CD4+ or CD8+ T cells and as IFN-γ–FITC geometric mean fluorescence 
intensity (MFI). Data are from 2 mice pooled per genotype. SupBCG, 
soluble BCG antigens.
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gen-specific Th1 response to Listeria monocytogenes (LM) has been 
reported to be MyD88 independent (25). These results contrast with 
a preferential Th2 response induced by parasites (17, 26, 27) and 
soluble antigens such as ovalbumin in the absence of MyD88 (18). 
In this last study, maturation of DCs by mycobacteria was reported 
to require MyD88 (18), whereas we show here a strong expression of 
costimulatory molecules in response to live M. bovis BCG in MyD88-
deficient DCs. A possible explanation for the difference between the 
2 studies may be the use of heat-killed H37Ra, as we show that heat-
killed mycobacteria have strong TLR2 agonist signaling through 
MyD88, whereas live BCG is able to stimulate some cytokine and 
costimulatory expression independent of TLR2 (28, 29).
A further strong argument for the emergence of adaptive immu-
nity in the absence of MyD88 is the fact that BCG vaccination 
conferred an initial protection to acute MTB infection. Vaccinat-
ed MyD88–/– mice displayed a rapid recruitment and activation of 
lymphocytes to the lung with little inflammation and controlled 
pulmonary infection, like wild-type mice, while nonvaccinated 
MyD88–/– mice developed fatal necrotic pneumonia within 4 
weeks of MTB challenge.
Clearly, although MyD88-deficient mice presented a defect of 
immediate proinflammatory cytokine release in the airways after 
local administration of mycobacteria (our unpublished data), 
nonvaccinated MyD88-deficient mice showed highly increased 
levels of IL-1β, IFN-γ, and TNF as compared with nonvacci-
nated control mice 4 weeks after MTB infection. The amount of 
cytokines expressed in vivo seemed to correlate with the bacillary 
burden, which was highest in nonvaccinated MyD88-deficient 
mice at this time point. Vaccination was associated with lower 
cytokine secretion in MyD88-deficient mice, along with lower 
bacterial load in the lungs.
Therefore, the MyD88-deficient host is able to compensate for 
the absence of the MyD88 signaling pathway in response to high 
Figure 6
BCG vaccination confers an initial pro-
tection to MTB-challenged MyD88–/– 
mice. MyD88–/– mice and control mice 
were either immunized by s.c. injection 
of M. bovis BCG (105 CFU) or left naive 
and 5 weeks later challenged by MTB 
H37Rv aerogenic infection (200 CFU 
per mouse i.n.). The mice were moni-
tored for body weight (A) or survival (B) 
or were sacrificed at 4 weeks after MTB 
challenge and analyzed for lung weight 
(C) and bacterial counts (D) as in Fig-
ure 2 (A: n = 7–8 mice per group from 
1 representative experiment out of 2; 
B: n = 11–13 mice per group from 2 exper-
iments; C and D: n = 4 per group from 
1 representative experiment out of 3; 
*P ≤ 0.05; **P ≤ 0.01).
Figure 7
BCG vaccination prevents necrotic pneumonia by aerogenic MTB in 
MyD88–/– mice. Lung tissue from BCG-vaccinated MyD88–/– (A, C, 
and E) and wild-type (B, D, and F) mice was analyzed at 4 weeks 
after MTB H37Rv infection (200 CFU i.n.). Lungs of MyD88–/– mice 
display small nodules (A), similar to vaccinated wild-type mice (B). 
Microscopic examination reveals a striking increase of mononuclear 
cells including abundant lymphocytes in the lungs of vaccinated and 
infected MyD88–/– and wild-type mice (C–F; H&E). Low-power micro-
graphs of representative lung sections are shown in C and D (mag-
nification, ×50), and higher magnification shows details in E and F 
(magnification, ×400).
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mycobacterial burden by triggering alternative pathways lead-
ing to increased cytokine secretion. Macrophages and DCs from 
MyD88-deficient mice show minute cytokine or nitrite production 
upon stimulation with mycobacterial antigens in vitro, but their 
response is not null. In fact, similarly low levels of TNF, IL-12 p40, 
or IL-6 are obtained after stimulation of MyD88-deficient APCs by 
mycobacteria or by LPS. LPS is a recognized TLR4 agonist using 
both MyD88-dependent and MyD88-independent pathways, the lat-
ter involving the adaptor TRIF (30). TRIF has been implicated in an 
IFN-β autocrine/paracrine loop leading to costimulatory molecule 
expression independent of MyD88. We show that live mycobacteria 
are also able to induce expression of costimulatory molecules such 
as CD40 or CD86 in MyD88-deficient macrophages and DCs, simi-
lar to LPS. In addition, since mycobacteria interact with other recep-
tors including scavenger, mannose, and complement receptors as 
well as DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN), TLR-
independent signaling pathways might provide proinflammatory 
signals. Identifying which of these pathways contribute to the 
MyD88-independent cytokine response to high mycobacterial infec-
tion, or initiate the adaptive response to mycobacteria, will require 
the generation of double-deficient mice for these receptors.
To address the mechanism of the vigorous inflammatory 
response in the lung of MTB-infected MyD88-deficient mice, we 
Figure 8
Cell recruitment in the lungs of vaccinated and MTB-challenged MyD88–/– 
mice. MyD88–/– and control mice were immunized by s.c. injection of 
M. bovis BCG (105 CFU) and 5 weeks later challenged by MTB aero-
genic infection (200 CFU) as in Figure 6. Leukocytes from infected lung 
were isolated 4 weeks after infection and analyzed by flow cytometry 
for CD44 expression in CD4- and CD8-positive T cells (A and B); for 
CD11b-, CD11c-, and Ly-6G–positive cells (B); and for MHC class II 
IA–IE expression (C) as in Figure 4. Results are expressed as absolute 
numbers of positive cells. Mean ± SD from 2 MyD88–/– mice are shown 
and are representative of 2 independent experiments.
Figure 9
The high pulmonary levels of cytokines and chemokines in MTB-infected MyD88–/– mice is reduced upon vaccination. Cytokine and chemokine 
concentrations were determined in lung homogenates from MyD88–/– and control mice immunized by s.c. injection of M. bovis BCG (105 CFU) 
and challenged 5 weeks later by MTB aerogenic infection (200 CFU) as in Figure 6. IL-1β (A), IFN-γ (B), TNF (C), MIP-1α (D), MCP-1 (E), and 
RANTES (F) were quantified by SearchLight protein array. Results are expressed as mean ± SD from 4 mice per group (*P ≤ 0.05; **P ≤ 0.01).
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measured chemokine levels in lung homogenates of both non-
vaccinated and vaccinated mice. Levels of RANTES, MCP-1, and 
MIP-1α were strongly increased in the lungs of nonvaccinated 
MyD88-deficient mice, correlating with the high bacillary burden 
in these mice 4 weeks after MTB infection. The increased levels 
of chemokines are likely to account for the increased influx of 
neutrophils and macrophages into the lungs of MyD88-deficient 
mice. Therefore, these data may suggest a more severe pneumo-
nitis and vigorous inflammatory response in conjunction with 
higher bacterial burden, and increased secretion of cytokines and 
chemokines, in MyD88-deficient mice.
The present results were not predicted by the recent report 
showing unimpaired killing of MTB in vitro by IFN-γ–stimulated 
MyD88–/– macrophages (31). However, the same study demon-
strated that the IFN-γ inducibility of several genes was dramati-
cally reduced in MyD88–/– macrophages, favoring the hypothesis 
that the innate immune system is hyporesponsive or nonrespon-
sive (31). Further, we show reduced TNF and IL-6 production by 
IFN-γ–stimulated MyD88–/– lung macrophages (Figure 1, G and H), 
which may contribute to the increased susceptibility to MTB infec-
tion, as IL-6–deficient mice are highly susceptible to high-dose sys-
temic MTB infection (32), although they could contain bacterial 
growth after low-dose aerosol infection (33).
In order to link innate and antigen-specific T cell responses, 
the present results suggest that MTB antigens recognized by 
TLRs or other PRRs might signal through MyD88-independent 
pathways, allowing antigen-specific immunity to develop in the 
absence of MyD88. Since the T cell response emerges late dur-
ing MTB infection, the MyD88–/– host with a profound defect of 
innate immunity is confronted with a load of virulent bacteria 
that is too high and therefore uncontrollable.
We hypothesize that there may be an immediate component 
of the innate immune response in the absence of MyD88, suffi-
cient to initiate an adaptive immune response, which is able to 
control the growth of nonvirulent bacteria. In a second phase of 
established cellular adaptive response, the long-term containment 
of infection requires a competent innate system. Along this line, 
systemic infection of MyD88-deficient mice with the nonvirulent, 
attenuated M. bovis BCG leads to a long-term control of the infec-
tion (24), whereas TNF-deficient mice succumb within 5 weeks 
under the same conditions (23). Thus, a nonvirulent infection 
may be controlled, even if the initial innate response is deficient. 
In the case of the BCG vaccination, the enhanced T cell response 
with release of IFN-γ activates MyD88-deficient APCs, which have 
a reduced but residual function, allowing the initial control of a 
virulent MTB infection (Figure 6). However, the defect of APCs is 
only temporarily compensated for, and the vaccinated mice start 
to succumb to infection after 2 months. The present data demon-
strate that absence of MyD88 signaling precludes long-term con-
trol of chronic MTB infection, as shown previously in TLR2- or 
TLR4-deficient mice (10, 14).
The possibility that absence of IL-18 and/or IL-1 signaling 
were also responsible for the defect observed in MyD88–/– mice 
cannot be excluded, although previous reports on MTB infec-
tion of IL-18–/– (34), IL-1β–/–, or IL-R1–/– mice showed less-strik-
ing defects in host resistance (35, 36). Under our experimen-
tal conditions, caspase-1–deficient mice (37) did not show an 
enhanced susceptibility to MTB infection, as they controlled 
acute infection and survived for more than 6 months without 
loss of body weight (data not shown).
Recently, MyD88-deficient mice were shown to be sensitive to 
an intravenous Mycobacterium avium infection, an opportunistic 
pathogen found in immunosuppressed individuals. MyD88-
deficient mice succumbed within 9–14 weeks to systemic M. 
avium infection with reduced early neutrophil recruitment in 
the liver and a profound defect in IFN-γ response (21). There 
are substantial differences in the host response to MTB versus 
M. avium infection, not the least being that the clearance of M. 
avium is enhanced in the absence of iNOS (38), while the same 
enzyme is critical to control MTB infection (39). A normal con-
trol and granuloma formation in response to MTB infection in 
the absence of MyD88 has been reported (40). The discrepancy 
with the results presented here may be related to differences in 
the virulence of the strain used, the Kiruno strain of MTB, or in 
the protocol and follow-up of infection. By contrast, increased 
susceptibility of MyD88-deficient mice to MTB infection has 
been shown in a low-dose aerosol infection (41). Here, we dem-
onstrate T cell priming to mycobacterial antigens in the absence 
of MyD88, in contrast to results from M. avium (21) and MTB 
infection (41). However, T cell priming in the absence of MyD88 
has been shown for another intracellular pathogen, LM. In fact, 
only a modest impairment of CD4 response and a normal CD8 
response to LM was reported in immunized MyD88–/– mice, and 
transfer of primed CD8 T cells from MyD88–/– mice conferred 
protection to LM infection (25). Therefore, the data from our 
studies and those involving LM infection suggest that adaptive 
immunity can be generated and provide total or partial protec-
tive immunity in the absence of MyD88.
In summary, our data show that MyD88 signaling is essential 
for efficient mycobacteria-induced cytokine and NO produc-
tion, while the expression of costimulatory molecules on APCs 
is not affected. This initial defect of innate response is associ-
ated with rapid death upon MTB infection, as the MyD88-defi-
cient mice cannot control the infection although they exhibit 
an antigen-specific T cell response. Second, the antigen-specific 
cellular immunity is MyD88 independent, explaining the partial 
protection to MTB infection by BCG vaccination. Indeed, BCG 
vaccination primed a T cell response and allowed the initial con-
trol of virulent MTB infection. Third, as a result of the profound 
defect of the innate immune response, MyD88–/– mice are unable 
to durably control the infection despite the adaptive response. 
Therefore, the development of innate immunity to intracellular 
pathogen MTB is MyD88-dependent, while adaptive immunity 
develops in the absence of MyD88.
Methods
Mice. MyD88–/– (15) and TNF–/– mice (42) backcrossed on the C57BL/6 
background (N10 and N6, respectively) were bred in our specific patho-
gen-free animal facility at CNRS. For experiments, adult (8- to 15-week-
old) animals were kept in sterile isolators in a biohazard animal unit. The 
infected mice were monitored regularly for clinical status and weighed 
weekly. Permission was obtained from the Regional Ethics Committee for 
Animal Experiments of Toulouse, France, for analysis of murine models of 
mycobacterial infection.
Bacteria and infection. MTB H37Rv (Pasteur) and M. bovis BCG (Pasteur 
strain 1173P2) were grown to mid-log phase in Middlebrook 7H9 liquid 
medium (Difco Laboratories), supplemented with 10% oleic acid/albu-
min/dextrose/catalase (OADC; Difco Laboratories) at 37°C. Aliquots 
were prepared and frozen at –80°C. Before use, an aliquot was thawed, 
briefly vortexed, and diluted in sterile saline containing 0.04% Tween 20, 
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and clumping was disrupted by 20 repeated aspirations through a 29-
gauge needle (Omnican). Pulmonary infection with MTB H37Rv was 
performed by delivering approximately 200 bacteria into both nasal cavi-
ties (20 μl each) under xylazine-ketamine anesthesia, and the inoculum 
size was verified by sacrificing mice 48 hours after infection and deter-
mining bacterial load in the lungs of infected mice. Furthermore, we 
compared the intranasal (i.n.) route of infection with that induced by 
the aerosol generator using the Middlebrook chamber (Glas-Col) as 
described previously (10) and confirmed effective and comparable lung 
infection (data not shown).
Vaccination with M. bovis BCG. MyD88–/– and C57BL/6 mice were inject-
ed s.c. with 105 CFU M. bovis BCG as described previously (43). Five 
weeks later, mice were infected i.n. with MTB H37Rv (200 CFU). Half of 
the mice were sacrificed 4 weeks later for histology and CFU determina-
tion, and the other half were used for a survival study. The experiments 
were performed twice.
Bacterial load in tissues. Bacterial loads in the lung, liver, and spleen of 
infected mice were evaluated at different time points after infection with 
MTB H37Rv as described (44). Organs were weighed and defined aliquots 
were homogenized in 0.04% Tween 20 PBS. Tenfold serial dilutions of 
organ homogenates were plated in duplicates onto Middlebrook 7H10 
agar plates containing 10% OADC and incubated at 37°C. Colonies were 
enumerated at 3 weeks and results are expressed as log10 CFU per organ.
Histopathological analysis. For histological analysis, lungs were removed 
at different time points of infection from both wild-type and MyD88–/– 
mice (12 and 14 mice, respectively), fixed in 4% phosphate-buffered 
formalin and embedded in paraffin. Two- to 3-micron sections were 
stained with H&E and a modified Ziehl-Neelsen stain. The latter 
involved staining in a prewarmed (60°C) carbol-fuchsin solution for 10 
minutes followed by destaining in 20% sulphuric acid and 90% ethanol 
before counterstaining with methylene blue.
Fluorescence-activated cell-sorting analysis of infiltrating cells from infected lung. 
FACS analysis of inflammatory cells from infected lung was performed as 
described (45, 46). In brief, mice were deeply anesthetized with xylazine-
ketamine and perfused with 0.02% EDTA-PBS until the tissue turned 
white. After removal, lung tissue was sliced into 1- to 2-mm3 pieces and 
was incubated in RPMI 1640 (Invitrogen Corp.) containing 5% FCS, anti-
biotics (100 U/ml penicillin and 100 μg/ml streptomycin), 10 mM HEPES 
(Invitrogen Corp.), collagenase (150 U/ml), and DNase (50 U/ml; Sigma-
Aldrich). After 1.5 hours of incubation at 37°C, single-cell suspension 
was obtained by vigorous pipetting. Cells were washed 3 times in PBS 
containing 0.01% NaN3 and 0.5% BSA and were then stained according to 
antibody manufacturer protocols. Rat anti-mouse CD4–peridinin-chlo-
rophyll-protein complex (PerCP; clone RM4-5), CD8-FITC (clone 53-6.7), 
CD44-PE (clone IM7), Ly6G-PE (clone RD6-8C5), CD11b-PE (clone 
M1/70), I-A/I-E-FITC (clone 2G9), CD19-PerCP-Cy5-5 (clone 1D3), and 
hamster anti-mouse CD11c-APC (clone HL3) were purchased from BD 
Biosciences — Pharmingen. Stained cells were washed twice, fixed with 
1% paraformaldehyde (FACS Lysing Solution; BD), and analyzed by flow 
cytometry on a LSR analyzer (BD). A large gate including myeloid and 
lymphoid cells and excluding only very low forward scatter (FSC) cells 
was used. Data were processed with CellQuest software (BD Biosciences 
— Immunocytometry Systems).
Interstitial lung macrophage isolation. Lung cells obtained as described above 
(46) were washed twice in HBSS with 2% of FCS and antibiotics and resus-
pended in RPMI supplemented with 10% FCS, 2 mM L-glutamin, antibi-
otics, 1% nonessential amino acids, 1 mM pyruvate, and 10 mM HEPES. 
The cell suspension (20 × 106 cells in 10 ml) was incubated for 1.5 hours 
on 90-mm–diameter Petri dishes (Costar-Corning) at 37°C. Nonadherent 
cells were removed by triple vigorous washing with warm HBSS containing 
2% of FCS. Adherent cells were detached from the plastic by incubating the 
monolayers in 0.02% EDTA-HBSS for 30 minutes at room temperature. 
Cell suspensions were obtained by pipetting, washed twice with HBSS/FCS, 
and resuspended in culture medium.
Primary macrophage and DC cultures. Murine BM cells were isolated from 
femurs and differentiated into macrophages after culturing at 106 cells/ml 
for 7 days in DMEM (Sigma-Aldrich) supplemented with 20% horse serum 
and 30% L929 cell-conditioned medium as a source of M-CSF (47). Three 
days after washing and reculturing in fresh medium, the cell prepara-
tion contained a homogenous population of macrophages. Alternatively, 
murine BM cells were differentiated into myeloid DCs after culturing 
(change on days 3, 6, and 8) at 2 × 105 cells/ml for 10 days in RPMI supple-
mented with 10% FCS and 4% J558L cell-conditioned medium as a source 
of GM-CSF as described previously (48).
Stimulation of macrophages and DCs. BM-derived macrophages, pulmonary 
macrophages, and DCs were plated in 96-well microculture plates (at 105 
cells per well) and stimulated with LPS (Escherichia coli, serotype O111:B4 
[Sigma-Aldrich] at 100 ng/ml) or MTB H37Rv (heat-killed for 40 minutes 
at 80°C; 2 bacteria per cell) or infected with M. bovis BCG or MTB H37Ra 
(both from Pasteur Institute; at a MOI of 2 bacteria per cell). Cell super-
natants were harvested after 24 hours of stimulation in the presence of 
IFN-γ (100 U/ml) for TNF, IL-12 p40, and IL-6 quantification using com-
mercial ELISA (Duoset; R&D Systems) and nitrite measurements by Griess 
reagents as described previously (49).
Antigen-specific IFN-γ production. T cell priming was assessed by the pro-
duction of IFN-γ upon antigen restimulation ex vivo. Single-cell suspen-
sions of splenocytes were prepared from wild-type and MyD88–/– mice 4 
weeks after s.c. immunization with 105 live M. bovis BCG. Splenocytes were 
cultured at 5 × 105 cells/ml in RPMI 1640 with glutamine, 5% FCS, and 
antibiotics and stimulated with 2.5 μg/ml concanavalin A (Con A; Sigma-
Aldrich), a lyophilized soluble fraction from BCG culture (10 μg/ml), or 
HKLM (100 bacteria per cell) for 2 days at 37°C. IFN-γ production in the 
supernatant was quantified by ELISA (Duoset; R&D Systems). Alterna-
tively, splenocytes from BCG-infected mice restimulated as above were 
analyzed for intracellular IFN-γ staining of CD4+ or CD8+ T cells: after 
12 hours of restimulation, addition of GolgiStop to block protein trans-
port, and incubation for an additional 6 hours, cells were labeled with anti-
CD4–PerCP (clone RM4-5) or CD8-APC (clone 53-6.7) antibodies, fixed, 
and permeabilized, and intracellular IFN-γ was stained with antibodies to 
IFN-γ–FITC (clone XMG1.2; according to BD Cytofix/Cytoperm kit man-
ual; all reagents from BD Biosciences).
Cutaneous DTH reaction. DTH reaction was performed as described previ-
ously (44). MyD88-deficient and control mice were vaccinated with 105 
live M. bovis BCG (s.c.). Three weeks later, mice were injected with 20 IU 
tuberculin/purified protein derivative (PPD; Bovituber; Merial) in 50 μl in 
the left footpad. Swelling was measured 48 hours later with a micrometer 
(Mitotuyo) and compared with that in the saline-injected right footpad.
Preparation and analyses of lung homogenates for cytokine/chemokine deter-
mination. At day 25 after infection, mice were deeply anesthetized with 
xylazine-ketamine and perfused with 0.02% EDTA-PBS until the tissue 
turned white. Whole lungs were harvested, weighed, and placed in 0.5 
ml of 4°C PBS solution. The contents were transferred into sterile 50-ml 
plastic tubes and homogenized in Dispomix homogenizer (Medic Tools) 
for 20 seconds at 6,000 rpm. Homogenates were centrifuged at 20,200 g, 
sterilized by filtration through a 0.22-μm filter (Costar-Corning), and 
stored at –80°C until determination of IL-1β, IL-10, IL-12 p70, IFN-γ, 
TNF-α, MIP-1α, JE (MCP-1), RANTES, and TGF-β levels by SearchLight 
protein array technology (Perbio).
Statistical analysis. Analysis was performed using Student’s t and ANOVA 
tests and P values less than or equal to 0.05 were considered significant.
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